Pink Sheet Executive Editor Derrick Gingery, Senior Reporter Maaisha Osman and Editor-in-Chief Nielsen Hobbs discuss the potential impact of the US Food and Drug Administration’s new updated guidance describing the one-trial plus confirmatory evidence standard for effectiveness (:47) and the significance of advancing yet another priority of former Commissioner Martin Makary (6:47). They also talk about the details of the agency’s planned pilot program to streamline IND clearances, including questions about the program’s feasibility. (14:08).

More On These Topics From The Pink Sheet

US FDA Rewrites Effectiveness Playbook, Positions

US FDA IND Reform Pilot Would Let ‘Qualified’ Outside

Clinical operations plays a decisive role in execution quality, data integrity, cost control, and development speed, yet it is often treated as a cost centre rather than a strategic function. In this episode, Claire Riches, VP, Clinical Solutions, Citeline is joined by Executive Consultant, Clinical Development Operations to discuss why clinical operations must be elevated into board‑level conversations. Together, they explore how clinops drives value, manages risk, and shapes long‑term development strategy, and what boards and executives need to understand to make better, more informed decisions.

View the video series and find out more information here: https://www.citeline.com/biotech

In this episode of the China biopharma English-language podcast, Xu Hu talks about China’s drug regulator finalizing trial data protection measures for drugs registered in the country, and some of the impacts these may have on future licensing deals involving the China market and company strategies in managing product lifecycle and market access in China.

Here are links to the stories this episode is based on:

Impact Of China’s New Data Protection On Deals, Corporate Strategies;

China Finalizes Data Protection Periods;

China Plans Clinical Data Protection By Product Category For First Time

Pancreatic cancer has the lowest survival rate of any major cancer — just 13%, largely because it's so hard to catch early. Changing that takes more than a lab breakthrough. It takes the unglamorous infrastructure to collect, track, and safeguard patient samples across dozens of institutions, reliably enough that researchers can trust what they find.

In this episode, host Krishna talks with Margaret Caspler, President and CEO of the PRECEDE Foundation — a consortium of more than 65 academic medical centers working to raise pancreatic cancer survival from 13% to 50% — and Kathi Shea, Chief Client Solutions Officer for Repository at Azenta Life Sciences, who has spent three decades in biorepository science. Together they explore why early detection has lagged, what it takes to run a biospecimen network at scale, and how a public-private partnership can do what neither side could alone.

Follow Medtech Insight to stay ahead of every shift in the device and diagnostics landscape.

This debut video episode of the In Vivo podcast examines the successes and pitfalls of the commercial launch of Yescarta (axicabtagene ciloleucel), Kite Pharma’s CAR-T therapy for relapsed/refractory large B-cell lymphoma. David Wild, senior reporter at In Vivo, is joined by Harris Kaplan, who consulted on the launch and conducted interviews with physicians, nurses, and hospital administrators before and after it, and is managing partner of Litmys, a life sciences commercial strategy consulting firm; Diane Parks, who led the Yescarta launch for Kite; and Jim Haag, a patient who received CAR-T therapy. It's a candid, unfiltered look at the gap between what innovation promises and what the healthcare system actually delivers.

Here are some of Harris Kaplan’s contributed articles for In Vivo:

Commercialization 3.0: Achieving New Product Success In Health Care’s New Era

Commercialization 3.0: Recognizing And Managing The Human Side Of Change

Physician Behavioral Inertia: Innovation’s Greatest Enemy

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年6月19日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: 辉瑞公司阐明肿瘤学发展方向；2026年国际生物技术大会（BIO 2026）的重点议题；GLP-1药物获取问题给肥胖症研究带来困扰；来自巴西的GLP-1药物使用洞察；以及第一季度销量前十的药物。

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-VFPFSBHMSVH33HNSZ6ND3ST45Q/

Audio roundup of selected biopharma industry content from Scrip over the business week ended June 19, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.

This time–Pfizer lays out oncology direction; key topics at BIO 2026; GLP-1 access causes problems for obesity studies; GLP-1 use insights from Brazil; and Q1’s top 10 drugs.

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-VFPFSBHMSVH33HNSZ6ND3ST45Q/

The Generics Bulletin Podcast: Probing The Patent Monopoly With I-MAK’s Tahir Amin

AI, Philips, Healthtech, Future Health Index 2026

Prevention has moved to the centre of UK health policy, with the NHS 10-year plan promising a decisive shift away from treatment. The financial case for getting there is less widely understood. In this episode of the Over the Counter Podcast, HBW Insight's David Ridley speaks to Liz Hampson, life sciences and health innovation advisory partner at Deloitte, about the firm's recent work on the socioeconomic value of prevention. Hampson explains why every pound invested in prevention returns an estimated £9.20, why early intervention pays off most, and how rising out-of-pocket spending risks creating a two-tier system. The conversation also covers the gender health gap in prevention, the underused role of community pharmacy, and Hampson's argument that health literacy is where consumer health companies can make the greatest difference.